Whether your personal interests are in supporting innovation, bringing lifesaving biomedical products to patients, training the next generation of biomedical leaders or fueling our economy, the Center for Biotechnology provides a vehicle to accomplish great things. Things that matter. Things that change, and save, lives.
Your involvement is an essential part of our future. Please consider a gift to the Center for Biotechnology which will help fuel innovation by ensuring that lifesaving technologies make it out of research labs and into the hands of patients.
Give to the Center for Biotechnology online through the Stony Brook Foundation. Contributions can be made to our Fund for Excellence. More information about donating through the Stony Brook Foundation can be found here.
Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.
BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.
Application deadline: October 29, 2026, 5:00pm ET
For info sessions, eligibility and deadlines visit our REACH Website and FAQ.
The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.
Questions? Reach out to our program contacts or sign up for office hours:
[post_title] => BioREACH: Translational Research Funding Opportunity
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => bioreach-translational-research-funding-opportunity
[to_ping] =>
[pinged] =>
[post_modified] => 2026-09-04 11:55:36
[post_modified_gmt] => 2026-09-04 15:55:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=5065
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 2219
[post_author] => 3
[post_date] => 2016-05-27 14:46:48
[post_date_gmt] => 2016-05-27 14:46:48
[post_content] => MIDI Medical Product Development, recently cut the ribbon new headquarters in a newly constructed Medical Center of Excellence, within Smithtown’s Village of the Branch.
The 15,100 square foot facility is accelerating MIDI’s rapid growth and presence in the medical/healthcare product development industry. The site was chosen based upon its pristine location, professional environment, and proximity to their collaborating partner Stony Brook University Medical Center.
MIDI specializes in meeting FDA regulatory standards for medical devices and provides market research and product engineering and design services for the biotech and medical industries.
[post_title] => MIDI Opens New Long Island Headquarters
[post_excerpt] => MIDI Medical Product Development, recently cut the ribbon new headquarters in a newly constructed Medical Center of Excellence, within Smithtown’s Village of the Branch.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => midi-opens-new-long-island-headquarters
[to_ping] =>
[pinged] =>
[post_modified] => 2016-06-07 14:56:29
[post_modified_gmt] => 2016-06-07 14:56:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2219
[menu_order] => 180
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 3048
[post_author] => 3
[post_date] => 2018-08-23 19:48:21
[post_date_gmt] => 2018-08-23 19:48:21
[post_content] => Two specific funding programs have been designed to help faculty, physicians, surgeons, medical fellows, and post-docs develop their academic innovations toward commercial goals: Feasibility - up $50k/12 months (director costs) and Proof of Concept- up to $100k/12 months (direct cost) . Full details and application materials can be found here.
Faculty members, physicians, post-doctoral associates, and BEIRs who are considering the submission of an application are strongly encouraged to discuss the proposal with
Anton Xavier (anton.xavier@stonybrook.edu); William Hanes (william.hanes@stonybrook.edu) and/or Emily Kao (Emily.Kao@stonybrook.edu) at the LIBH prior to writing a full proposal..
Deadline for submission is September 19th, 2018. All proposal should be submitted through the online portal. Please note an approval from your Sponsored Programs Office is NOT required prior to the submission but will be required if the project is selected for NIH secondary review. Eligible applicants will be notified if their application is selected to move forward.
The LIBH is supported by the National Institutes of Health REACH initiative (Research Evaluation and Commercialization Hub), our four partner institutions, The Research Foundation for SUNY, and Empire State Development.
[post_title] => Long Island Bioscience Hub (LIBH) Technology Development RFP
[post_excerpt] => Proposals for the 7th round of the Long Island Bioscience Hub (LIBH) Technology Development Funding are now being accepted with the deadline of September 19th, 2018.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-bioscience-hub-libh-technology-development-rfp
[to_ping] =>
[pinged] =>
[post_modified] => 2018-08-23 19:48:21
[post_modified_gmt] => 2018-08-23 19:48:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=3048
[menu_order] => 113
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 4534
[post_author] => 4
[post_date] => 2024-04-08 13:47:00
[post_date_gmt] => 2024-04-08 17:47:00
[post_content] =>
The Center for Biotechnology has announced the appointment of Dr. Dee Dao as Associate Director for Business Development and Investment. In her new role, Dr. Dao will serve as the primary contact on issues related to research, technology development and commercialization for the Center for Biotechnology. Additionally, Dr. Dao will foster new collaborative relationships in order to bolster sponsored research agreements and strategic alliances.
Prior to joining the CFB, Dr. Dao served as a Venture Associate for the NYU Innovation Venture Fund, where she focused on investment opportunities in life science and healthcare. Prior to NYU, Dr. Dao was at the Ludwig Institute for Cancer Research where she contributed to early oncology therapeutic development planning and oversaw intellectual property (IP) strategy to support the clinical development of the Institute’s therapeutics. Before that, Dr. Dao investigated bacterial virulence and immunity to identify new vaccines against Tuberculosis as a postdoctoral fellow in an HHMI laboratory at Albert Einstein College of Medicine.
Currently, Dr. Dao also serves as a mentor for entrepreneurs participating in the Entrepreneurship Lab, a NYCEDC initiative. Dr. Dao received a Ph.D. in Molecular Genetics/Developmental Biology at Columbia University and a B.S. in Chemistry from University of Pittsburgh. Dr. Dao is also an alumnus of the Center for Biotechnology’s Fundamentals of the Bioscience Program in 2010.
“We are thrilled to have Dee join the Center for Biotechnology to lead our technology and business development efforts on behalf of innovators and emerging companies in New York” Diane Fabel, Director of Operations at the Center for Biotechnology said. She continued “Dee brings deep experience working with and funding innovation to her role at the Center which our clients and community will greatly benefit from.”
“I am very happy to join the team at the Center for Biotechnology. I’ve admired the work the Center for Biotechnology has done when it comes to supporting and accelerating the development of biomedical technology in New York State” Dr. Dao said. “I’m looking forward to helping lead the technology and business development efforts of the Center and increase the impact the organization can have on the wealth of innovations in the region”.
[post_title] => Dr. Dee Dao Appointed Associate Director for Business Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => dr-dee-dao-appointed-associate-director-for-business-development
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-24 12:42:43
[post_modified_gmt] => 2025-02-24 17:42:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4534
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 5065
[post_author] => 4
[post_date] => 2026-09-01 14:03:32
[post_date_gmt] => 2026-09-01 18:03:32
[post_content] =>
Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.
BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.
Application deadline: October 29, 2026, 5:00pm ET
For info sessions, eligibility and deadlines visit our REACH Website and FAQ.
The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.
Questions? Reach out to our program contacts or sign up for office hours: